Hamel Lawrence G 4
4 · ACELRX PHARMACEUTICALS INC · Filed Mar 4, 2019
Insider Transaction Report
Form 4
Hamel Lawrence G
Chief Development Officer
Transactions
- Purchase
Common Stock
2019-02-28$2.81/sh+3,682$10,346→ 78,053 total
Holdings
- 29,795(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Balance includes non-reportable acquisition of 3,682 shares of Common Stock through the Company's Employee Stock Purchase Plan.